TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Arbor Biotechnologies Stock

Arbor Biotechnologies Stock

arbor.bioHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $231.6MM

Arbor Biotechnologies uses AI and machine learning to develop gene editing therapeutics that aim to treat genomic diseases. Their current pipeline focuses on liver and Central Nervous System (CNS) diseases. Arbor Biotechnologies was founded in 2016 by David Scott Ph.D., Winston Yan Ph.D., David Walt Ph.D., and Feng Zhang Ph.D. and is headquartered in Cambridge, MA.

Buy or sell Arbor Biotechnologies stockLearn more about Arbor Biotechnologies IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Arbor Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Arbor Biotechnologies’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Arbor Biotechnologies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Arbor Biotechnologies investors also invested in these private companies

Tao Capital Partners
Arch Venture Partners
GreatPoint Ventures
Section 32
TCG Crossover Management
Ridgeback Capital

Team

Management Team

David Cheng
Chief Technology Officer
John Murphy
Chief Scientific Officer
David Scott Ph.D
Co-Founder & Head of Innovation
Winston Yan Ph.D
Co-Founder & Head of Translational Strategy
Devyn Smith Ph.D
Chief Executive Officer & Board Member
Pam Stetkiewicz Ph.D
Chief Operating Officer

Board Members

Chen-Ming Yu MD
TCG Crossover Management
Keith Crandell
ARCH Venture Partners

Frequently Asked Questions About Arbor Biotechnologies’ Stock

plusminus
Can you buy Arbor Biotechnologies’ stock?
Arbor Biotechnologies is not publicly traded on NYSE or NASDAQ in the U.S. To buy Arbor Biotechnologies’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Arbor Biotechnologies’ stock?
Yes, you can sell stock of a private company like Arbor Biotechnologies. Forge can help you sell your Arbor Biotechnologies stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Arbor Biotechnologies’ stock price?
Arbor Biotechnologies is a privately held company and therefore does not have a public stock price. However, you may access Arbor Biotechnologies’ private market stock price with Forge Data.
plusminus
What is Arbor Biotechnologies’ stock ticker symbol?
Arbor Biotechnologies does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Arbor Biotechnologies in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Seeking Alpha 01/11/2023
Vertex, Arbor Biotechnologies extend agreement on precision gene editing technology
Vertex Pharmaceuticals (NASDAQ:VRTX) and Arbor Biotechnologies have extended a collaboration agreement that will provide the former with rights to the latter's novel precision editing technology for up to three diseases.
The Street 11/01/2022
After Prime Medicine, What's the Next Gene Editing IPO?
Investors enjoyed a record number of biotech IPOs in 2020 and 2021 as companies raced to grab bags of money from public markets flooded with liquidity. The pipeline has dried up considerably in 2022, primarily due to tightening financial conditions. It's not quite as fun, but it's a sign of healthy markets.
The Science Advisory Board 10/17/2022
Gene editing advances continue a pace, but progress is still early: panel
With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa (MOTM) say they are looking forward to other near- and longer-term breakthrough technologies on the horizon.

Trending Companies

Frequently Asked Questions

Updated on: Apr 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.